BG Medicine (BGMD) Receives News Impact Score of 0.29
News headlines about BG Medicine (NASDAQ:BGMD) have trended positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BG Medicine earned a news impact score of 0.29 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.5247837685986 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
BG Medicine (BGMD) traded up 1.842% during midday trading on Tuesday, reaching $0.047. The company’s stock had a trading volume of 468 shares. BG Medicine has a 12 month low of $0.03 and a 12 month high of $0.18. The stock’s 50-day moving average price is $0.05 and its 200-day moving average price is $0.06. The firm’s market capitalization is $531993.00.
BG Medicine Company Profile
BG Medicine, Inc (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation.
Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.